Protection Against Severe Clinical Outcomes With Adenovirus or Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Patients Hospitalized With Coronavirus Disease 2019.

Llibre, Josep M; Revollo, Boris; Aguilar, Sergi; Calomarde-Gomez, Cristina; Bruguera, Andreu; Martin-Iguacel, Raquel

Llibre, Josep M; Revollo, Boris; Aguilar, Sergi; Calomarde-Gomez, Cristina; Bruguera, Andreu; Martin-Iguacel, Raquel.

Llibre JM; Infectious Diseases Division, University Hospital Germans Trias, Badalona, Spain.
Revollo B; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
Aguilar S; Infectious Diseases Division, University Hospital Germans Trias, Badalona, Spain.
Calomarde-Gomez C; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
Bruguera A; Internal Medicine, University Hospital Germans Trias, Badalona, Spain.
Martin-Iguacel R; Rheumatology Department, University Hospital Germans Trias, Badalona, Spain.

J Infect Dis ; 226(5): 938-940, 2022 09 13.

Article in English | MEDLINE | ID: covidwho-2029042

Subject(s)

COVID-19; SARS-CoV-2; Adenoviridae/genetics; COVID-19/prevention & control; COVID-19 Vaccines; Humans; RNA, Messenger; SARS-CoV-2/genetics

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: J Infect Dis Year: 2022 Document Type: Article Affiliation country: Infdis

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google